SPTBN1 inhibits growth and epithelial-mesenchymal transition in breast cancer by downregulating miR-21

Huijie Wu  ¹ , Shuyi Chen  ¹ , Chenyang Liu  ¹ , Jiajia Li  ² , Xiangxiang Wei  ¹ , Mengping Jia  ¹ , Jieyu Guo  ¹ , Jiayu Jin  ¹ , Dan Meng  ¹ , Xiuling Zhi  ³ Affiliations

• PMID: 34358482
• DOI: 10.1016/j.ejphar.2021.174401

Abstract

SPTBN1 (spectrin beta, non-erythrocytic 1) has been linked to tumor progression and epithelial-mesenchymal transition (EMT). However, the role of SPTBN1 has yet to be investigated in breast cancer. This study aimed to evaluate the viability, growth, and migration ability of the breast cancer cell line MDA-MB-231 and BT549 using CCK-8 assay, xenograft models, and Transwell assays. The expression of SPTBN1, EMT-related genes, and miRNA21 in breast cancer cells and tissues were assessed by quantitative real-time polymerase chain reaction (qPCR) and Western blot. SPTBN1 staining of breast cancer tissues was analyzed by the Human Protein Atlas databases. Both chromatin immunoprecipitation qPCR and immunofluorescence were performed to detect how SPTBN1 regulates miRNA21. Our results showed that the expression of SPTBN1 in primary breast cancer tumors was dramatically lower than that in normal tissues and that lower levels of SPTBN1 were associated with significantly shorter progression-free survival. We also discovered that the loss of SPTBN1 promotes EMT, the viability of MDA-MB-231 and BT549 in vitro, and the growth of MDA-MB-231 tumor xenografts in vivo by upregulating miR-21 level. Furthermore, loss of SPTBN1-mediated miR-21 upregulation was dependent on the stability and nuclear translocation of NF-κB p65. Therefore, SPTBN1 is a pivotal regulator that inhibits EMT and the growth of breast cancer.

Keywords: Breast cancer; EMT; NF-κB p65; SPTBN1; miR-21.